Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

被引：0
|
作者：
Lu, S. [1 ]
Cheng, Y. [2 ]
Huang, D. [3 ]
Sun, Y. [4 ]
Wu, L. [5 ]
Zhou, C. [6 ]
Zhou, J. [7 ]
Guo, Y. [8 ]
Chen, L. [9 ]
Shao, J. [9 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Caner Ctr, Shanghai, Peoples R China
[2] Jilin Canc Hosp, Dept Thorac Oncol, Changchun, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Dept Thorac Oncol, Tianjin, Peoples R China
[4] Shandong Univ, Jinan Cent Hosp, Dept Oncol, Jinan, Peoples R China
[5] Hunan Canc Hosp, Dept Thorac Med 2, Changsha, Peoples R China
[6] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis,Resp Med Dept, ffiliated Hosp 1,Guangzhou Inst Resp Hlth, Guangzhou, Peoples R China
[7] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Resp Dis, Hangzhou, Peoples R China
[8] Tongji Univ, Sch Med, Shanghai East Hosp, Dept Med Oncol, Shanghai, Peoples R China
[9] Eli Lilly & Co, Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Selpercatinib; RET fusion-positive NSCLC; China; ORR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA02.01
引用
收藏
页码：S888 / S889
页数：2
相关论文
共 50 条
  • [21] RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape
    Novello, Silvia
    Califano, Raffaele
    Reinmuth, Niels
    Tamma, Antonella
    Puri, Tarun
    ONCOLOGIST, 2023, 28 (05): : 402 - 413
  • [22] Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer
    Nguyen, Ly
    Monestime, Shanada
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (07) : 527 - 533
  • [23] Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
    Fangdi Sun
    Caroline E. McCoach
    Current Treatment Options in Oncology, 2021, 22
  • [24] Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
    Cho, Byoung Chul
    Chiu, Chao-Hua
    Massarelli, Erminia
    Buchschacher, Gary L.
    Goto, Koichi
    Overbeck, Tobias R.
    Loong, Herbert H. F.
    Chee, Cheng E.
    Garrido, Pilar
    Dong, Xiaorong
    Fan, Yun
    Lu, Shun
    Schwemmers, Sven
    Bordogna, Walter
    Zeuner, Harald
    Osborne, Stuart
    John, Thomas
    LUNG CANCER, 2024, 188
  • [25] Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer
    Sun, Fangdi
    McCoach, Caroline E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (08)
  • [26] Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
    Subbiah, Vivek
    Gainor, Justin F.
    Oxnard, Geoffrey R.
    Tan, Daniel Shao-Weng
    Owen, Dwight Hall
    Cho, Byoung Chul
    Loong, Herbert H. F.
    McCoach, Caroline Elizabeth
    Weiss, Jared
    Kim, YuJung
    Bazhenova, Lyudmila
    Park, Keunchil
    Daga, Haruko
    Besse, Benjamin
    Gautschi, Oliver
    Ng, Sarah
    Huang, Xin
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Real-world outcomes of chemoimmunotherapy and selective RET inhibitors in Chinese patients with RET fusion-positive non-small cell lung cancer
    Wan, Rui
    Li, Weihua
    Wang, Zhijie
    Zhong, Jia
    Lin, Lin
    Duan, Jianchun
    Wang, Jie
    HELIYON, 2024, 10 (02)
  • [28] Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion plus Non-Small Cell Lung Cancer
    Zhou, Q.
    Wu, Y.
    Chang, J.
    Wang, H.
    Fan, Y.
    Zhao, J.
    Wu, G.
    Sun, Y.
    Sun, M.
    Wang, X.
    Shi, H.
    Nian, W.
    Wang, K.
    Zheng, X.
    Qu, L.
    Yao, S.
    Shen, Z.
    Li, P.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S889 - S890
  • [29] Selpercatinib in Chinese patients with RET-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the randomized LIBRETTO-321 phase II trial
    Lu, Shun
    Cheng, Ying
    Huang, Dingzhi
    Sun, Yuping
    Wu, Lin
    Zhou, Chengzhi
    Zhou, Jianying
    Guo, Ye
    Shao, Jingxin
    Zhang, Wanli
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [30] Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers
    Gautschi, O.
    Subbiah, V
    Konda, B.
    Bauer, T.
    McCoach, C.
    Falchook, G.
    Takeda, M.
    Patel, J.
    Weiss, J.
    Peled, N.
    Bazhenova, L.
    Soldatenkova, V
    French, P.
    Drove, N.
    Drilon, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 12 - 12
12345